Skip to main content
editorial
. 2016 Oct 5;2(4):193–197.

Table 4.

Week 96 results from Phase 3 randomised trials of first-line tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) [23]

Treatment arms: TAF/FTC/EVG/c TDF/FTC/EVG/c
(n=866) (n=867)
HIV RNA <50 copies/mL 87% 85%
Virological failure 5% 5%
Drug resistance 1.2% 0.9%
Grade 3 or 4 clinical adverse events 12% 12%
Grade 3 or 4 laboratory adverse events 28% 25%

c: cobicistat; EVG: elvitegravir; FTC: emtricitabine; TAF: tenofovir alafenamide; TDF: tenofovir disoproxil fumarate.